Whittle Sarah B, Williamson Kaitlin C, Russell Heidi V
a Department of Pediatrics, Section of Hematology-Oncology , Texas Children's Cancer and Hematology Centers, Baylor College of Medicine , Houston , TX , USA.
b Department of Pediatrics , Texas Children's Hospital, Baylor College of Medicine , Houston , TX , USA.
Pediatr Hematol Oncol. 2017 Aug;34(5):331-342. doi: 10.1080/08880018.2017.1396386. Epub 2017 Dec 4.
High-risk neuroblastoma is an aggressive childhood cancer with poor outcomes. Treatment begins with an induction phase comprised of intense multi-agent chemotherapy with the goal of maximally reducing tumor bulk. Given the high intensity of induction chemotherapy, neutropenic fever and infectious complications are common; however, the actual incidence is difficult to determine from clinical trial reports. We performed a retrospective review of infection-related complications in 76 children treated for high-risk neuroblastoma at Texas Children's Hospital. Medical records were reviewed for demographics, febrile neutropenia (FN) episodes, presence, and type of bacterial and fungal infections, and potential risk factors for infection. Fifty-seven percent of patients developed one or more serious bacterial or fungal infections during induction chemotherapy. Additionally, over 75% of patients had at least one admission for FN. Risk factors for developing any infection included female sex, MYCN amplification, and having Medicaid. Patients with external central venous catheters and those requiring parenteral nutrition had higher rates of bacteremia or fungemia. Each cycle, 50% were readmitted for either FN or infection. The overall burden of infectious complications was high, with 70% having two or more unplanned admissions for infection or FN. The incidence of febrile neutropenia and serious bacterial and fungal infections during induction chemotherapy for high-risk neuroblastoma is high. Most patients had at least two additional hospitalizations for infectious complications. Risk factors including female sex, MYCN amplification, payer status, and type of central access were associated with higher rates of infection in this cohort.
CLABSI Central line associated blood stream infection; CTCAE Common Terminology Criteria for Adverse Events; FN Febrile neutropenia; ANC Absolute neutrophil count; TPN Total parenteral nutrition.
高危神经母细胞瘤是一种侵袭性儿童癌症,预后较差。治疗始于诱导期,包括强化多药化疗,目标是最大程度地缩小肿瘤体积。鉴于诱导化疗强度高,中性粒细胞减少性发热和感染并发症很常见;然而,从临床试验报告中难以确定实际发生率。我们对德克萨斯儿童医院76例接受高危神经母细胞瘤治疗的儿童的感染相关并发症进行了回顾性研究。审查了病历中的人口统计学资料、发热性中性粒细胞减少(FN)发作情况、细菌和真菌感染的存在及类型,以及感染的潜在危险因素。57%的患者在诱导化疗期间发生了一种或多种严重细菌或真菌感染。此外,超过75%的患者因FN至少有一次住院治疗。发生任何感染的危险因素包括女性、MYCN扩增和拥有医疗补助。有外周中心静脉导管的患者和需要肠外营养的患者发生菌血症或真菌血症的几率更高。每个周期,50%的患者因FN或感染再次入院。感染并发症的总体负担很高,70%的患者因感染或FN有两次或更多次计划外住院。高危神经母细胞瘤诱导化疗期间发热性中性粒细胞减少以及严重细菌和真菌感染的发生率很高。大多数患者因感染并发症至少还有两次住院治疗。在该队列中,包括女性、MYCN扩增、支付者状态和中心通路类型在内的危险因素与较高的感染率相关。
CLABSI中心静脉导管相关血流感染;CTCAE不良事件通用术语标准;FN发热性中性粒细胞减少;ANC绝对中性粒细胞计数;TPN全胃肠外营养